H.C. Wainwright assumed coverage of Xeris Biopharma (XERS) with a Buy rating and $10 price target The firm believes the commercial potential of the company’s commercial portfolio remains “meaningfully underappreciated.” The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: